RxDoctor Payments Data

Lawand Saadulla, MD

Nephrology · Hilliard, OHNPI 1801009451

Payments from drug & device makers

$3,776in general payments, 2019–2025

Across 205 payments — averaging $18.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$442
  • Otsuka America Pharmaceutical, Inc.$353
  • OPKO Pharmaceuticals, LLC$327
  • Amgen$283
  • ANI Pharmaceuticals, Inc.$262
  • Boehringer Ingelheim$253
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$3,27087%
  • Education$50513%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,776 in reported general payments places this provider in the 70th percentile of 450 nephrology providers in Ohio.

See all nephrology providers in Ohio

Medicare billing

Part B allowed, 2024
$69,008
Medicare patients
202
Services billed
584

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RayaldeeCalcifediol46$62,944
KerendiaFinerenone58$49,936
FarxigaDapagliflozin Propanediol47$47,011
JardianceEmpagliflozin29$25,608
Sevelamer Carbonate60$7,079
Calcitriol143$2,027
Nifedipine ErNifedipine12$827
Hydralazine Hcl72$619
Doxazosin Mesylate47$517
Cefdinir43$474
Tamsulosin Hcl27$434
Losartan Potassium35$382
Bumetanide14$350
Vitamin D2Ergocalciferol (Vitamin D2)30$335
Amlodipine Besylate55$331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
OPKO Pharmaceuticals, LLCRayaldee$327$62,94446 claims
BayerKerendia$442$49,93658 claims
AstraZenecaFarxiga$127$47,01147 claims
Boehringer IngelheimJardiance$253$25,60829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 450 nephrology providers in Ohio.

Other nephrology in Hilliard

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →